An ovotestis is a gonad with both testicular and ovarian aspects. In humans, ovotestes are an infrequent anatomical variation associated with gonadal dysgenesis. The only mammals where ovotestes are not symptomatic of an intersex variation are moles, wherein females possess ovotestes along with a masculinized clitoris. These ovotestes in nonpregnant female moles secrete eight times as much testosterone as the ovotestes of pregnant moles. In invertebrates that are normally hermaphroditic, such as most gastropods (snails and slugs) in the clade Eupulmonata, an ovotestis is a common feature of the reproductive anatomy. In mice, ovotestes are structured such that the central region is testicular tissue while the poles both contain ovarian tissue. Experiments involving the SOX9 gene, which is initiated by the SRY region of the Y chromosome, have shown the gene’s requirement for testicular differentiation from the presence of ovotestis formation within XX Sox9 trangenic mice. (6)  Ovotestis within B6-XYPOS mice allow for gonadal development research within the same tissue to take place in ways previously unavailable. In gastropods
An ovotestis or hermaphroditic gland (Latin: glandula hermaphroditica), is found as normal anatomical feature in the reproductive system of some gastropods including such species as the land snail Cornu aspersum. People with Ovotestis
Anton Krzyzanowski

See also
Intersex
True hermaphroditism


== References ==
Olopatadine/mometasone, sold under the brand name Ryaltris, is a fixed-dose combination medication for the treatment of allergic rhinitis and rhinoconjunctivitis in adults and adolescents twelve years of age and older. It contains olopatadine hydrochloride and mometasone furoate monohydrate. It is sprayed into the nose.Common side effects include an unpleasant taste (dysgeusia).It was approved for medical use in Australia in December 2019, and in the United States in January 2022. References
External links
"Olopatadine". Drug Information Portal. U.S. National Library of Medicine. "Mometasone furoate". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT02631551 for "Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR) (GSP 301-301)" at ClinicalTrials.gov
Clinical trial number NCT02870205 for "Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR) (GSP 301-304)" at ClinicalTrials.gov